AIMS/HYPOTHESIS: Intramyocellular lipid accumulation and insulin resistance are thought to be due to reduced lipid oxidation in a human model of high risk of developing type 2 diabetes. METHODS: We studied 32 offspring of type 2 diabetic parents and 32 control individuals by means of DXA, indirect calorimetry, insulin clamp and 1H MRS of the calf muscles, and differences between and within study groups were analysed before and after segregation by quartiles of fasting lipid oxidation. RESULTS: In comparison with control subjects, the offspring showed impaired insulin sensitivity, which was associated with higher fasting intramyocellular lipid content (Spearman's rho -0.35; p=0.04), but fasting lipid oxidation did not differ between groups (1.21+/-0.46 vs. 1.25+/-0.37 mg.kg(-1) lean body mass per min; p=0.70). Nevertheless, offspring in the lowest quartile of lipid oxidation had the most severe impairment of insulin sensitivity and a strong association was shown between lipid oxidation and insulin sensitivity within quartiles (Spearman's rho 0.47; p=0.01); this was not observed within the control group (Spearman's rho 0.13; p=0.47). Intramyocellular lipid content was not significantly different within quartiles of lipid oxidation in either of the groups. CONCLUSIONS/ INTERPRETATION: Insulin sensitivity improved across increasing quartiles of fasting lipid oxidation in the offspring group, but remained constant in the control group, supporting the hypothesis that impaired fat oxidation is a primary pathogenic factor of insulin resistance in people with a genetic background for type 2 diabetes. Despite their association with impaired insulin sensitivity, soleus and tibialis anterior intramyocellular lipid content remained constant across increasing quartiles of fasting lipid oxidation within both groups.
AIMS/HYPOTHESIS: Intramyocellular lipid accumulation and insulin resistance are thought to be due to reduced lipid oxidation in a human model of high risk of developing type 2 diabetes. METHODS: We studied 32 offspring of type 2 diabetic parents and 32 control individuals by means of DXA, indirect calorimetry, insulin clamp and 1H MRS of the calf muscles, and differences between and within study groups were analysed before and after segregation by quartiles of fasting lipid oxidation. RESULTS: In comparison with control subjects, the offspring showed impaired insulin sensitivity, which was associated with higher fasting intramyocellular lipid content (Spearman's rho -0.35; p=0.04), but fasting lipid oxidation did not differ between groups (1.21+/-0.46 vs. 1.25+/-0.37 mg.kg(-1) lean body mass per min; p=0.70). Nevertheless, offspring in the lowest quartile of lipid oxidation had the most severe impairment of insulin sensitivity and a strong association was shown between lipid oxidation and insulin sensitivity within quartiles (Spearman's rho 0.47; p=0.01); this was not observed within the control group (Spearman's rho 0.13; p=0.47). Intramyocellular lipid content was not significantly different within quartiles of lipid oxidation in either of the groups. CONCLUSIONS/ INTERPRETATION:Insulin sensitivity improved across increasing quartiles of fasting lipid oxidation in the offspring group, but remained constant in the control group, supporting the hypothesis that impaired fat oxidation is a primary pathogenic factor of insulin resistance in people with a genetic background for type 2 diabetes. Despite their association with impaired insulin sensitivity, soleus and tibialis anterior intramyocellular lipid content remained constant across increasing quartiles of fasting lipid oxidation within both groups.
Authors: Claus Thamer; Jürgen Machann; Oliver Bachmann; Michael Haap; Dominik Dahl; Beate Wietek; Otto Tschritter; Andreas Niess; Klaus Brechtel; Andreas Fritsche; Claus Claussen; Stephan Jacob; Fritz Schick; Hans-Ulrich Häring; Michael Stumvoll Journal: J Clin Endocrinol Metab Date: 2003-04 Impact factor: 5.958
Authors: Seng Khee Gan; Adamandia D Kriketos; Bronwyn A Ellis; Campbell H Thompson; Edward W Kraegen; Donald J Chisholm Journal: Diabetes Care Date: 2003-06 Impact factor: 19.112
Authors: S Jacob; J Machann; K Rett; K Brechtel; A Volk; W Renn; E Maerker; S Matthaei; F Schick; C D Claussen; H U Häring Journal: Diabetes Date: 1999-05 Impact factor: 9.461
Authors: Seng Khee Gan; Adamandia D Kriketos; Ann M Poynten; Stuart M Furler; Campbell H Thompson; Edward W Kraegen; Lesley V Campbell; Donald J Chisholm Journal: Obes Res Date: 2003-11
Authors: Jose E Galgani; Neil M Johannsen; Sudip Bajpeyi; Sheila R Costford; Zhengyu Zhang; Alok K Gupta; Eric Ravussin Journal: Obesity (Silver Spring) Date: 2011-06-16 Impact factor: 5.002
Authors: Douglas E Befroy; Kitt Falk Petersen; Sylvie Dufour; Graeme F Mason; Robin A de Graaf; Douglas L Rothman; Gerald I Shulman Journal: Diabetes Date: 2007-02-07 Impact factor: 9.461
Authors: C Ekman; T Elgzyri; K Ström; P Almgren; H Parikh; Marloes Dekker Nitert; T Rönn; Fiona Manderson Koivula; C Ling; Å B Tornberg; P Wollmer; K F Eriksson; L Groop; O Hansson Journal: J Appl Physiol (1985) Date: 2015-09-03
Authors: J Kahlhöfer; M Lagerpusch; J Enderle; B Eggeling; W Braun; D Pape; M J Müller; A Bosy-Westphal Journal: Eur J Clin Nutr Date: 2014-07-09 Impact factor: 4.016